Triclosan: A review of effectiveness and safety in health care settings

American Journal of Infection Control

Volumn 28, Issue 2, 2000, Pages 184-196

  Jones, Rhonda D ^a,b   Jampani, Hanuman B ^a,b   Newman, Jerry L ^a,b   Lee, Andrew S ^a,b  

^a Sci and Regulatory Consult Inc   (United States)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRICLOSAN;

ANTIMICROBIAL ACTIVITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; INFECTION CONTROL; NONHUMAN; REVIEW;

EID: 0034007314     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1067/mic.2000.102378     Document Type: Article

References (65)

1. 1. Bhargava HN, Leonard PA. Triclosan: applications and safety. AJIC Am J Infect Control 1996;24:209-18.
2. 2. Ciba-Geigy Corporation. Irgasan7DP300: Broad Spectrum Antimicrobial. High Point (NC): Ciba-Geigy Corporation; April, 1995.
3. 3. DeSalva SJ, Kong BM, Lin YJ. Triclosan: a safety profile. Am J Dentistry 1989;2:185-96.
4. 4. Larson EL. American Practitioners of Infection Control guidelines for infection control practice: guideline for use of topical antimicrobial agents. AJIC Am J Infect Control 1988;16:253-66.
5. 5. Larson EL. American Practitioners of Infection Control guidelines for infection control practice: APIC guideline for hand washing and hand antisepsis in health care settings. AJIC Am J Infect Control 1995;23:251-69
6. 6. Reybrouck G. Hand washing and hand disinfection. J Hosp Infect 1986;8:5-23.
7. 7. Ciba-Geigy Corporation. Irgasan7 DP300: Physical and Chemical Parameters. Document No. 2514E. May 11, 1991.
8. 8. Food and Drug Administration. OTC topical antimicrobial products and drug and cosmetic products proposed rules. 39 Federal Register 33102-33141 (September 6, 1974).
9. 9. Food and Drug Administration. Topical antimicrobial products tentative final monograph. 43 Federal Register 1210-1249 (January 6, 1978).
10. 10. Food and Drug Administration. Tentative final monograph for health-care antiseptic drug products; proposed rule. 59 Federal Register 31402-31451 (June 17, 1994).
11. 11. Food and Drug Administration. FDA approves first toothpaste for gum disease. FDA Talk Paper 1997 July 14.
12. 12. Federally Registered Pesticides. 2nd ed. Port Huron (MI): North American Compendiums, Inc; 1993.
13. 13. Kanetoshi A, Katsura E, Ogawa H, Ohyama T, Kaneshima H, Miura T. Acute toxicity, percutaneous absorption and effects on hepatic mixed function oxidase activities of 2,4,4′-trichloro-2′-hydroxydiphenyl ether (Irgasan7DP300) and its chlorinated derivatives. Arch Environ Contamination Toxicology 1992;23:91-8.
14. 14. Black JG, Howes D, Rutherford T. Percutaneous absorption and metabolism of Irgasan7DP300. Toxicology 1975;3:33-47.
15. 15. Waaler SM, Rolla G, Skjorland KK, Ogaard B. Effects of oral rinsing with triclosan and sodium lauryl sulfate on dental plaque formation: a pilot study. Scand J Dental Res 1993;101:192-5.
16. 16. Barkvoll P, Rolla G. Triclosan protects the skin against dermatitis caused by sodium lauryl sulphate exposure. J Clin Periodontol 1994;21:717-9.
17. 17. Coleman EJ, Espositio A, Afflitto J, Gaffar A. Triclosan prevents SLS-cytotoxicity to human gingival fibroblasts. J Dental Res 1993;72:1837.
18. 18. Ciba-Geigy Corporation, Inc. Diphenyl compounds which inhibit arachidonic acid metabolism and their use in pharmaceutical compositions. US Patent 5,185,377. 1993.
19. 19. Unilever, Inc. Oral compositions containing Triclosan for the treatment of aphthous ulcer. Patent WO 94/26258. 1994.
20. 20. Unilever, Inc. Use of triclosan for the manufacture of a medicament for the treatment of periodontitis. Patent EP 0528468A1. 1992.
21. 21. Meincke BE, Kranz RG, Lynch DL. Effect of Irgasan on bacterial growth and its adsorption into the cell wall. Microbios 1980;28:133-47.
22. 22. Nissen HP, Ochs D. Triclosan. Cosmetics Toiletries 1998;113:61-4.
23. 23. Sastzu M, Shimizu K, Noguchi N, Kono M. Triclosan-resistant Staphylococcus aureus [letter]. Lancet 1993;341:20.
24. 24. McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis. Nature 1998;394:531-2.
25. 25. Tattawasart U, Maillard JY, Furr JR, Russell AD. Development of chlorhexidine and antibiotic resistance in Pseudomonas stutzeri. Proceedings of the 98th General Meeting of the American Society for Microbiology; May 1998; Atlanta, Ga. p. 533.
26. 26. McMurry LM, Oethinger M, Levy SB. Overexpression of marA, soxS, or acrAB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli. FEMS Micro Lett 1998;166:305-9.
27. 27. Russell AD, Maillard JY, Furr JR. Possible link between bacterial resistance and use of antibiotics and biocides. Antimicrob Agents Chemother 1998;42:2151.
28. 28. Heath RJ, Yuo YT, Shapiro MA, Olson E, Rock CO. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J Biol Chem 1998;273:30316-20.
29. 29. Russell AD. Plasmids and bacterial resistance to biocide. J Appl Microbiol 1997;82:155-65.
30. 30. Uhl S. Triclosan-resistant Staphylococcus aureus [letter]. Lancet 1993;342:248.
31. 31. Sastzu M, Shimizu K, Noguchi N, Kono M. Triclosan-resistant Staphylococcus aureus-Author's Reply [letter]. Lancet 1993; 342:248.
32. 32. McDonnell G, Pretzer, D. Action and targets of triclosan. ASM News. 1998;64:670-1.
33. 33. Cox AR. Efficacy of the antimicrobial agent triclosan in topical deodorant products: Recent Developments in vivo. J Soc Cosmetic Chem 1987;38:223-31.
34. 34. Volpe AR, Petrone ME, De Vizio W, Davies RM. A Review of plaque, gingivitis, calculus and caries clinical efficacy studies with a dentifrice containing triclosan and PVM/MA copolymer. J Clin Dentistry Special Issue 1993;4:31-41.
35. 35. Jones CL, Ritchie JA, Marsh PD, Van Der Ouderaa F. The Effect of long-term use of a dentifrice containing zinc citrate and a non-ionic agent on the oral flora. J Dental Res 1988;67:46-50.
36. 36. Stephen KW, Saxton CA, Jones CL, Ritchie JA, Morrison T. Control of gingivitis and calculus by a dentifrice containing a zinc salt and triclosan. J Periodontol 1990;61:674-9.
37. 37. Gehring W, Forssman T, Jost G, Gloor M. The germ-reducing effect of erythromycin and triclosan in atopic dermatitis. Aktuelle Dermatol 1996;22:28-31.
38. 38. Ciba-Geigy Corporation. Irgasan7 DP300: highly effective antimicrobial for hand disinfectants. Document No. 2513E. 1990 Oct 3.
39. 39. Jampani H, Lee A, Newman J, Jones R. A comprehensive comparison of the in vitro and in vivo antimicrobial effectiveness of triclosan, chlorhexidine, alcohol/chlorhexidine, and poloxamer iodine topical formulations [abstract]. AJIC Am J Infect Control 1998;26:186.
40. 40. Ciba-Geigy Corporation. Letter to W. Gilbertson and attachments. FDA Public Docket 75N-183H. 1995 Dec 14.
41. 41. The Soap and Detergent Association and The Cosmetic, Toiletry, and Fragrance Association. Letter to W. Gilbertson and attachments. FDA Public Docket 75N-183H. 1995 June 13.
42. 42. The Soap and Detergent Association and The Cosmetic, Toiletry, and Fragrance Association. Letter to W. Gilbertson and attachments. FDA Public Docket 75N-183H. 1995 Dec 14.
43. 43. The Soap and Detergent Association and The Cosmetic, Toiletry, and Fragrance Association. Letter to W. Gilbertson and attachments. FDA Public Docket 75N-183H. 1995 Mar 15.
44. 44. Vischer WA, Regos J. Antimicrobial spectrum of Triclosan a broad spectrum antimicrobial agent. Zentralbl Baketeriol 1974;226:376-89.
45. 45. Sehulster LM, Anderson RL. Susceptibility of glycopeptide-intermediate resistant Staphylococcus aureus (GISA) to surface disinfectants, hand washing chemicals, and a skin antiseptic. Proceedings of the 98th General Meeting of the American Society for Microbiology; May 1998. p. 547.
46. 46. American Society of Testing and Materials. E1174-94 Standard test method for evaluation of health care personnel handwash formulation. The annual book of standards. 11.05:480-482. West Conshohocken (PA): ASTM; 1991.
47. 47. Benson L, Bush L, LeBlanc D. Importance of neutralizers in the stripping fluid in a simulated healthcare personnel handwash. Infect Control Hosp Epidemiol 1990;11:595-9.
48. 48. Bartzokas CA, Corkill JE, Makin T. Evaluation of the skin disinfecting activity and cumulative effect of chlorhexidine and triclosan handwash preparations on hands artificially contaminated with Serratia marcescens. Infect Control 1987;8(4):163-7.
49. 49. Bartzokas CA, Gibson MF, Graham R, Pinder DC. A comparison of triclosan and chlorhexidine preparations with 60 per cent isopropyl alcohol for hygienic hand disinfection. J Hosp Infection 1983;4:245-55.
50. 50. Sheena AZ, Stiles BE. Efficacy of germicidal hand wash agents against transient bacteria inoculated onto hands. J Food Protect 1983;46:722-7.
51. 51. Stiles BE, Sheena AZ. Efficacy of germicidal hand wash agents in use in a meat processing plant. J Food Protect 1987;50:289-95.
52. 52. Bartzokas CA, Corkill JE, Makin T, Parry E. Comparative evaluation of the immediate and sustained antibacterial action of two regimens, based on triclosan- and chlorhexidine-containing handwash preparations, on volunteers. Epidemiol Infect 1987;98:337-44.
53. 53. Faoagali J, Fong J, George N, Mahoney P, O'Rourke V. Comparison of the immediate, residual, and cumulative antibacterial effects of Novaderm R, Novascrub R, Betadine Surgical Scrub, Hibiclens, and liquid soap. AJIC Am J Infect Control 1995;23:337-43.
54. 54. Bartzokas CA, Corkill JE, Makin T, Pinder DC. Assessment of the remanent antibacterial effect of a 2% triclosan-detergent preparation on the skin. J Hyg Cambridge 1983;91:521-8.
55. 55. Huntington Laboratories, Inc. Letter to W. Gilbertson and attachments. FDA Public Docket 75N-183H. 1995 Dec 13.
56. 56. Mbithi JN, Springthorpe VS, Sattar SA. Comparative in vivo efficiencies of hand-washing agents against hepatitis A Virus (HM-175) and poliovirus type 1 (Sabin). Appl Environ Microbiol 1993;59:3463-9.
57. 57. Bellamy K, Alcock R, Babb JR, Davies JG, Ayliffe GA. A test for the assessment of "hygienic" hand disinfection using rotavirus. J Hosp Infect 1993;24:201-10.
58. 58. Zafar AB, Butler RC, Reese DJ, Gaydos LA, Mennonna PA. Use of 0.3% triclosan (Bacti-stat*) to eradicate an outbreak of methicillin-resistant Staphylococcus aureus in a neonatal nursery. AJIC Am J Infect Control 1995;23:200-8.
59. 59. Marshall PJ. Use of triclosan to reduce the incidence of M.R.S.A. Proceedings of the National Conference of the Australian Infection Control Association; May 7-9, 1997.
60. 60. Webster J. Hand-washing in a neonatal intensive care unit. Aust Coll Midwives Inc J 1991;4(2):25-7.
61. 61. Webster J. Hand washing in a neonatal intensive care nursery: product acceptability and effectiveness of chlorhexidine gluconate 4% and triclosan 1%. J Hosp Infect 1992;21:137-41.
62. 62. Webster J, Faogali JL, and Cartwright D. Elimination of methicillin-resistant Staphylococcus aureus from a neonatal intensive care unit after hand washing with triclosan. J Paediatr Child Health 1994;30:59-64.
63. 63. Tuffnell DJ, Croton RS, Hemingway DM, Hartely MN, Wake PN, Garvey RJP. Methicillin resistant Staphylococcus aureus; the role of antisepsis in the control of an outbreak. J Hosp Infect 1987;10:255-9.
64. 64. Brady LM, Thomson M, Plamer MA, Harkness JL. Successful control of endemic MRSA in a cardiothoracic surgical unit. Med J Aust 1990;1552:240-5.
65. 65. Wenzel RP, Pfaller MA. Hand washing: efficacy versus acceptance. A brief essay. J Hosp Infect 1991;18(B):65-8.